Global BioPharma Cold Chain Packaging Market Overview:
Any temperature-sensitive substance, such as frozen foods, blood components, stem cells, tissues, cells, vaccines, and infectious substances, that requires secure packaging to withstand the cold temperatures of storage containers throughout the transportation is referred to as a biopharma cold chain product. The sterility, safety, and viability of the biopharma items and specimens inside are ensured by secure packaging.
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Forecast Period | 2023-2028 |
Historical Period | 2018-2022 |
Unit | Value (USD Million) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
Influencing Trend:
Governments in developing nations are constantly updating their packaging industry requirements to ensure quality, and safety, and to avoid breakage, spillage, and contamination
Market Growth Drivers:
Growth in the biopharmaceutical and healthcare sector and Increase in the development of more complex biological-based medicines
Challenges:
Stringent government regulations
Restraints:
High cost associated with cold chain packaging
Opportunities:
Technological advancements and focus on improving the performance of packaging formats and Rising shipments of vaccines, hormone treatments, and complex proteins that require cold chain refinements to be transported at a controlled temperature
Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Amcor Plc (Switzerland), United Parcel Service Inc.(United States), DuPont de Nemours Inc.(United States), CCL Industries Inc. (Canada), Sonoco Products Co. (United States), Cryoport Inc. (United States), Cascades Inc (Canada), Cold Chain Technologies (United States), Intelsius (United Kingdom) and Pelican Products, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Softbox systems (United Kingdom) and Sofrigam (United States). Analyst at AMA Research see United States Players to retain maximum share of Global BioPharma Cold Chain Packaging market by 2028. Considering Market by End User, the sub-segment i.e. Hospitals will boost the BioPharma Cold Chain Packaging market.
Latest Market Insights:
On Feb 04, 2020, Pelican BioThermal announces the acquisition of NanoCool. This acquisition further increases the breadth of the Pelican BioThermal product portfolio, already the most comprehensive in the industry. The addition of NanoCool customers, market segments, and product technologies will enable Pelican BioThermal to expand its access to patients, laboratories, and other last-mile players in the distribution of life sciences materials and collection of patient laboratory samples.
On Sept. 15, 2020, Sonoco ThermoSafe announced that its new Pegasus ULD® bulk temperature-controlled container has received FAA (Federal Aviation Administration) approval as a unit load device (ULD)., and On June 30, 2020, Softbox announced the launch of Tempcell ECO, a new curbside-recyclable temperature control parcel shipper.
What Can be Explored with the BioPharma Cold Chain Packaging Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global BioPharma Cold Chain Packaging Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in BioPharma Cold Chain Packaging
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global BioPharma Cold Chain Packaging market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in BioPharma Cold Chain Packaging market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts And Strategic Business Planners, Biopharma Cold Chain Packaging Provider, Raw Material Suppliers, Dealers, Suppliers, Traders, And Distributors, Venture Capitalists And Private Equity Firms, Government Regulatory And Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.